A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT06083207 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: IBI3003

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.